RGNX REGENXBIO Inc

Price (delayed)

$18.2

Market cap

$791.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.25

Enterprise value

$812.26M

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, ...

Highlights
RGNX's EPS is up by 3.8% since the previous quarter
The net income is up by 3.6% from the previous quarter
RGNX's gross profit has dropped by 84% year-on-year but it is up by 15% since the previous quarter
The gross margin has declined by 30% year-on-year but it has increased by 18% since the previous quarter
The company's revenue has shrunk by 77% YoY and by 2.7% QoQ
The equity has contracted by 33% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of RGNX
Market
Shares outstanding
43.47M
Market cap
$791.08M
Enterprise value
$812.26M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
7.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.41
Earnings
Revenue
$109.64M
EBIT
-$250.44M
EBITDA
-$235.94M
Free cash flow
-$257.07M
Per share
EPS
-$6.25
Free cash flow per share
-$5.92
Book value per share
$10.7
Revenue per share
$2.52
TBVPS
$17.21
Balance sheet
Total assets
$747.83M
Total liabilities
$282.69M
Debt
$93.3M
Equity
$465.14M
Working capital
$276.87M
Liquidity
Debt to equity
0.2
Current ratio
3.46
Quick ratio
3.15
Net debt/EBITDA
-0.09
Margins
EBITDA margin
-215.2%
Gross margin
60.8%
Net margin
-246.5%
Operating margin
-234.9%
Efficiency
Return on assets
-31.6%
Return on equity
-49.7%
Return on invested capital
-34.7%
Return on capital employed
-39.4%
Return on sales
-228.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGNX stock price

How has the REGENXBIO stock price performed over time
Intraday
-0.33%
1 week
-9.18%
1 month
-1.09%
1 year
-9.81%
YTD
-19.75%
QTD
-3.75%

Financial performance

How have REGENXBIO's revenue and profit performed over time
Revenue
$109.64M
Gross profit
$66.7M
Operating income
-$257.51M
Net income
-$270.27M
Gross margin
60.8%
Net margin
-246.5%
RGNX's gross profit has dropped by 84% year-on-year but it is up by 15% since the previous quarter
The company's revenue has shrunk by 77% YoY and by 2.7% QoQ
The gross margin has declined by 30% year-on-year but it has increased by 18% since the previous quarter
The net income is up by 3.6% from the previous quarter

Growth

What is REGENXBIO's growth rate over time

Valuation

What is REGENXBIO stock price valuation
P/E
N/A
P/B
1.7
P/S
7.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.41
RGNX's EPS is up by 3.8% since the previous quarter
RGNX's P/B is 47% below its 5-year quarterly average of 3.2 and 6% below its last 4 quarters average of 1.8
The equity has contracted by 33% YoY and by 10% from the previous quarter
The company's revenue has shrunk by 77% YoY and by 2.7% QoQ
The price to sales (P/S) is 49% lower than the 5-year quarterly average of 14.2 but 39% higher than the last 4 quarters average of 5.2

Efficiency

How efficient is REGENXBIO business performance
The ROE is down by 6% QoQ
REGENXBIO's ROA has decreased by 4.3% from the previous quarter
The ROIC has contracted by 2.4% from the previous quarter

Dividends

What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGNX.

Financial health

How did REGENXBIO financials performed over time
RGNX's total assets is 165% greater than its total liabilities
RGNX's total assets is down by 27% year-on-year and by 10% since the previous quarter
RGNX's total liabilities is down by 16% year-on-year and by 11% since the previous quarter
REGENXBIO's debt is 80% lower than its equity
RGNX's debt to equity has soared by 54% year-on-year and by 11% since the previous quarter
The equity has contracted by 33% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.